Table of Content

Executive Summary
1 Technology Definition
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2 Market Scope
2.1 Key Questions Answered in the Report
3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market Overview
4.1 PD-1/PD-L1 Immunotherapy and Their Clinical Importance
4.2 PD-1/PD-L1 Immunotherapy Development and Commercialization Landscape
4.3 Global PD-1/PD-L1 Immunotherapy Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
4.6 Impact of COVID-19 on PD-1/PD-L1 Immunotherapy Market
5 Epidemiology of PD-1/PD-L1 Immunotherapy
6 Patent Landscape
7 Market Dynamics
7.1 Overview
7.2 Impact Analysis
7.3 Drivers
7.3.1 Rising Prevalence of Cancer
7.3.2 Unmet Medical Needs of Metastatic Cancer Patients
7.3.3 Advancements Made in the Field of Precision Medicine and Immuno-Oncology
7.3.4 Rising Awareness Among People for the Treatment of Cancer
7.3.5 Increasing Research and Development Expenditure in the Field of Oncology
7.3.6 Increase in Disposable Income
7.4 Restraints
7.4.1 Adverse Effects of PD-1/PD-L1 Immunotherapy
7.4.2 Payment Policy and Reimbursement Issue
7.4.3 High Development Cost of New Therapy
7.5 Opportunities
7.5.1 Developing Healthcare Infrastructure in Emerging Economies
8 Industry Insights
8.1 Overview
8.2 Regulatory Scenario
8.3 Legal Requirements and Frameworks in the U.S.
8.3.1 Clinical Trial Authorization
8.3.2 Marketing Authorization
8.3.3 USFDA Guidelines for BLA Submission
8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
8.4.1 EMA Biologics License Application Process
8.4.2 Centralized Procedure
8.4.3 Decentralized Procedure
8.4.4 Mutual-Recognition Procedure
8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
8.5.1 China
8.5.2 Japan
8.6 Expedited Regulatory Designations Around the World
9 Global PD-1/PD-L1 Immunotherapy Market (by Type), $Million, 2019-2030
9.1 Introduction
9.2 PD-1 Inhibitors
9.2.1 Commercialized Therapeutics
9.2.1.1 Keytruda
9.2.1.2 Opdivo
9.2.1.3 Libtayo
9.2.2 Pipeline Therapeutics
9.3 PD-L1 Inhibitors
9.3.1 Commercialized Therapeutics
9.3.1.1 Tecentriq
9.3.1.2 Imfinzi
9.3.1.3 Bavencio
9.3.2 Pipeline Therapeutics
10 Global PD-1/PD-L1 Immunotherapy Market (by Application), $Million, 2019-2030
10.1 Introduction
10.2 Non-Small Cell Lung Cancer (NSCLC)
10.3 Hepatocellular Carcinoma (HCC)
10.4 Esophageal Cancer
10.5 Small Cell Lung Cancer (SCLC)
10.6 Urothelial Carcinoma
10.7 Others
11 Global PD-1/PD-L1 Immunotherapy Market (by Region), $Million, 2019-2030
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Australia
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World
12 Competitive Landscape
12.1 Key Developments and Strategies
12.1.1 Regulatory and Legal Developments
12.1.2 Partnerships, Alliances, and Business Expansions
12.1.3 M&A Activities
12.1.4 Funding Activities
12.2 Market Share Analysis
13 Company Profiles
13.1 Overview
13.2 AstraZeneca Plc
13.2.1 Company Overview
13.2.2 Role of AstraZeneca Plc in the Global PD-1/PD-L1 Immunotherapy Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 BeiGene, Ltd.
13.3.1 Company Overview
13.3.2 Role of BeiGene, Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
13.3.3 Financials
13.3.4 Key Insights About Financial Health of the Company
13.3.5 SWOT Analysis
13.4 Bristol-Myers Squibb Company
13.4.1 Company Overview
13.4.2 Role of Bristol Myers Squibb Company in the Global PD-1/PD-L1 Immunotherapy Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
13.5.1 Company Overview
13.5.2 Role of Chia Tai Tianqing Pharmaceutical Group Co. Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Eli Lilly & Company
13.6.1 Company Overview
13.6.2 Role of Eli Lilly & Company in the Global PD-1/PD-L1 Immunotherapy Market
13.6.3 Financials
13.6.4 SWOT Analysis
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Company Overview
13.7.2 Role of F. Hoffmann-La Roche Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
13.7.3 Financials
13.7.4 Key Insights About Financial Health of the Company
13.7.5 SWOT Analysis
13.8 GlaxoSmithKline plc
13.8.1 Company Overview
13.8.2 Role of GlaxoSmithKline plc in the Global PD-1/PD-L1 Immunotherapy Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 Innovent Biologics, Inc.
13.9.1 Company Overview
13.9.2 Role of Innovent Biologics, Inc. in the Global PD-1/PD-L1 Immunotherapy Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.1 Jiangsu HengRui Medicine Co., Ltd.
13.10.1 Company Overview
13.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11 Merck & Co., Inc.
13.11.1 Company Overview
13.11.2 Role of Merck & Co., Inc. in the Global PD-1/PD-L1 Immunotherapy Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 Merck KGaA
13.12.1 Company Overview
13.12.2 Role of Merck KGaA in the Global PD-1/PD-L1 Immunotherapy Market
13.12.3 Financials
13.12.4 Key Insights About Financial Health of the Company
13.12.5 SWOT Analysis
13.13 Novartis AG
13.13.1 Company overview
13.13.2 Role of Novartis AG in the Global PD-1/PD-L1 Immunotherapy Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 Pfizer Inc.
13.14.1 Company Overview
13.14.2 Role of Pfizer Inc. in the Global PD-1/PD-L1 Immunotherapy Market
13.14.3 Financials
13.14.4 SWOT Analysis
13.15 Regeneron Pharmaceuticals Inc.
13.15.1 Company Overview
13.15.2 Role of Regeneron Pharmaceuticals, Inc. in the Global PD-1/PD-L1 Immunotherapy Market
13.15.3 Financials
13.15.4 Key Insights About Financial Health of the Company
13.15.5 SWOT Analysis
13.16 Sanofi S.A.
13.16.1 Company Overview
13.16.2 Role of Sanofi SA in the Global PD-1/PD-L1 Immunotherapy Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
List of Figures
Figure 1: NCI Fiscal Budget Year-on-Year, 2013-2018
Figure 2: Financial Burden of Cancer (2015)
Figure 3: Share of Prevalence of Cancer in Global Population
Figure 4: Number of People with Cancer (by Age) in Global Population
Figure 5: Global PD-1/PD-L1 Immunotherapy Market
Figure 6: Impact Analysis
Figure 7: Share of Key Developments and Strategies, June 2015-June 2020
Figure 8: Global PD-1/PD-L1 Inhibitors Market (by Type), 2019 and 2030
Figure 9: Global PD-1/PD-L1 Inhibitors Market (by Application), 2019 and 2030
Figure 10: Global PD-1/PD-L1 Inhibitors Market (by Region), 2019 and 2030
Figure 2.1: Global PD-1/PD-L1 Immunotherapy Market Segmentation
Figure 3.1: Global PD-1/PD-L1 Immunotherapy Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: PD-1/PD-L1 Clinical Trial Landscape
Figure 4.2: Global PD-1/PD-L1 Immunotherapy Market 2019-2030
Figure 4.3: Most Impacted Practices in the Treatment of Cancer
Figure 5.1: Prevalence of Melanoma Cancer in U.S. (Total Population)
Figure 5.2: Prevalence of Cervical Cancer in U.S. (Total Population)
Figure 5.3: Prevalence of Lung Cancer in U.S. (Total Population)
Figure 5.4: Prevalence of Renal Cell Carcinoma in U.S. (Total Population)
Figure 5.5: Prevalence of Squamous Cell Carcinoma of Head and Neck in U.S. (Total Population)
Figure 5.6: Target Population of Lung Cancer in U.S.
Figure 5.7: Target Population of Squamous Cell Carcinoma of Head and Neck in U.S.
Figure 5.8: Target Population of Renal Cell Carcinoma in U.S.
Figure 5.9: Target Population of Melanoma in U.S.
Figure 5.10: Target Population of Cervical Cancer in U.S.
Figure 6.1: Number of Patents Filed, January 2015-December 2019
Figure 6.2: Percentage of Patents Filed, By Patent Office, January 2015-December 2019
Figure 7.1: Number of People with Cancer (by Age) in Global Population
Figure 7.2: Household Disposable Income, US$/Capita
Figure 8.1: Steps for Obtaining Marketing Authorization
Figure 8.2: USFDA Review Timeline
Figure 8.3: EMA Review Timeline
Figure 9.1: Revenue Contribution of Different Segments, 2019 and 2030
Figure 9.2: Mechanism of Immunosuppression by PD-1/PD-L1 Axis
Figure 9.3: Global PD-1/PD-L1 Inhibitors Market (by PD-1 Inhibitors), 2019-2030
Figure 9.4: Global PD-1/PD-L1 Inhibitors Market (by PD-1 Inhibitors), 2019-2030
Figure 9.5: Global PD-1 Inhibitors Market (Keytruda), 2019-2030
Figure 9.6: Global PD-1 Inhibitors Market (Opdivo), 2019-2030
Figure 9.7: Global PD-1 Inhibitors Market (Libtayo), 2019-2030
Figure 9.8: Distribution of Drugs in Pipeline, by Phases
Figure 9.9: Global PD-1/PD-L1 Inhibitors Market (by PD-L1 Inhibitors), 2019-2030
Figure 9.10: Global PD-1/PD-L1 Inhibitors Market (by PD-L1 Inhibitors), 2019-2030
Figure 9.11: Global PD-L1 Inhibitors Market (Tecentriq), 2019-2030
Figure 9.12: Global PD-L1 Inhibitors Market (Imfinzi), 2019-2030
Figure 9.13: Global PD-L1 Inhibitors Market (Bavencio), 2019-2030
Figure 10.1: Revenue Contribution of Different Applications, 2019 and 2030
Figure 10.2: Global PD-1/PD-L1 Inhibitors Market (NSCLC), 2019-2030
Figure 10.3: Global PD-1/PD-L1 Inhibitors Market (HCC), 2019-2030
Figure 10.4: Global PD-1/PD-L1 Inhibitors Market (Esophageal Cancer), 2019-2030
Figure 10.5: Global PD-1/PD-L1 Inhibitors Market (Small Cell Lung Cancer), 2019-2030
Figure 10.6: Global PD-1/PD-L1 Inhibitors Market (Urothelial Carcinoma), 2019-2030
Figure 10.7: Global PD-1/PD-L1 Inhibitors Market (Others), 2019-2030
Figure 11.1: Global PD-1/PD-L1 Immunotherapy Market (by Region)
Figure 11.2 Global PD-1/PD-L1 Immunotherapy Market (by Region), 2019-2030
Figure 11.3: North America PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.4: North America: Market Dynamics
Figure 11.5: Revenue Contributions of Different Countries in North America, 2019 and 2030
Figure 11.6: U.S. PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.7: Canada PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.8: Europe PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.9: Europe: Market Dynamics
Figure 11.10: Revenue Contributions of Different Countries in Europe, 2019 and 2030
Figure 11.11: Germany PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.12: U.K. PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.13: France PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.14: Italy PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.15: Spain PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.16: Rest-of-Europe PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.17: Asia-Pacific PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.18: APAC: Market Dynamics
Figure 11.19: Revenue Contributions of Different Countries in Asia-Pacific, 2019 and 2030
Figure 11.20: China PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.21: Japan PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.22: India PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.23: South Korea PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.24: Australia PD-1/PD-L1 immunotherapy market, 2019-2030
Figure 11.25: RoAPAC PD-1/PD-L1 immunotherapy market, 2019-2030
Figure 11.26: Latin America PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.27: Latin America: Market Dynamics
Figure 11.28: Revenue Contributions of Different Countries in Latin America, 2019 and 2030
Figure 11.29: Brazil PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.30: Mexico PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.31: Rest-of-Latin America PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 11.32: RoW PD-1/PD-L1 Immunotherapy Market, 2019-2030
Figure 12.1: Share of Key Developments and Strategies, June 2015-June 2020
Figure 12.2: Regulatory and Legal Developments Share (by Company), June 2015-June 2020
Figure 12.3: Partnerships, Alliances, and Business Expansions (by Company), June 2015-June 2020
Figure 12.4: M&A Activities Share (by Company), June 2015-June 2020
Figure 12.5: Market Share Analysis (by Company), 2018 and 2019
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: AstraZeneca Plc: Overall Product Portfolio
Figure 13.3: AstraZeneca plc: Overall Financials, 2017-2019
Figure 13.4: AstraZeneca plc: Revenue (by Segment), 2017-2019
Figure 13.5: AstraZeneca plc: Revenue (by Region), 2017-2019
Figure 13.6: AstraZeneca plc: R&D Expenditure, 2017-2019
Figure 13.7: AstraZeneca plc: SWOT Analysis
Figure 13.8: BeiGene, Ltd.: Overall Product Portfolio (Approved in China)
Figure 13.9: BeiGene, Ltd.: Overall Financials, 2017-2019
Figure 13.10: BeiGene, Ltd.: Revenue (by Region), 2017-2019
Figure 13.11: BeiGene, Ltd.: R&D Expenditure, 2017-2019
Figure 13.12: BeiGene, Ltd.: SWOT Analysis
Figure 13.13: Bristol Myers Squibb Company: Overall Product Portfolio
Figure 13.14: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 13.15: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 13.16: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 13.17: Bristol Myers Squibb Company: SWOT Analysis
Figure 13.18: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: Pipeline Product Portfolio
Figure 13.19: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: Overall Financials, 2018-2019
Figure 13.20: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: R&D Expenditure, 2017-2019
Figure 13.21: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: SWOT Analysis
Figure 13.22: Eli Lilly & Company: Product Portfolio (China)
Figure 13.23: Eli Lilly & Company: Overall Financials, 2017-2019
Figure 13.24: Eli Lilly & Company: Revenue (by Region), 2017-2019
Figure 13.25: Key Insights About Financial Health of the Company
Figure 13.26: Eli Lilly & Company: SWOT Analysis
Figure 13.27: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 13.28: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.29: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 13.30: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 13.31: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.32: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 13.33: GlaxoSmithKline plc: Pipeline Product Portfolio
Figure 13.34: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 13.35: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 13.36: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 13.37: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 13.38: GlaxoSmithKline plc: SWOT Analysis
Figure 13.39: Innovent Biologics, Inc.: Product Portfolio (China)
Figure 13.40: Innovent Biologics, Inc.: Overall Financials, 2018-2019
Figure 13.41: Innovent Biologics, Inc.: R&D Expenditure, 2017-2019
Figure 13.42: Innovent Biologics, Inc.: SWOT Analysis
Figure 13.43: Jiangsu HengRui Medicine Co., Ltd.: Pipeline Product Portfolio
Figure 13.44: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, 2018-2019
Figure 13.45: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, 2017-2019
Figure 13.46: Jiangsu HengRui Medicine Co., Ltd.: SWOT Analysis
Figure 13.47: Merck & Co., Inc.: Product Portfolio
Figure 13.48: Merck & Co., Inc.: Overall Financials, 2017-2019
Figure 13.49: Merck & Co., Inc.: Revenue (by Segment), 2017-2019
Figure 13.50: Merck & Co., Inc.: Revenue (by Region), 2017-2019
Figure 13.51: Merck & Co., Inc.: R&D Expenditure, 2017-2019
Figure 13.52: Merck & Co., Inc.: SWOT Analysis
Figure 13.53: Merck KGaA: Product Portfolio
Figure 13.54: Merck KGaA: Overall Financials, 2017-2019
Figure 13.55: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 13.56: Merck KGaA: Revenue (by Region), 2017-2019
Figure 13.57: Merck KGaA: R&D Expenditure, 2017-2019
Figure 13.58: Merck KGaA: SWOT Analysis
Figure 13.59: Novartis AG: Overall Financials, 2017-2019
Figure 13.60: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 13.61: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.62: Novartis AG: R& D Expense, 2017-2019
Figure 13.63: Novartis AG: SWOT Analysis
Figure 13.64: Pfizer Inc.: Overall Product Portfolio
Figure 13.65: Pfizer Inc.: Overall Financials, 2017-2019
Figure 13.66: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 13.67: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 13.68: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 13.69: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 13.70: Pfizer Inc.: SWOT Analysis
Figure 13.71: Regeneron Pharmaceuticals, Inc.: Overall Product Portfolio
Figure 13.72: Regeneron Pharmaceuticals, Inc.: Overall Financials, 2017-2019
Figure 13.73: Regeneron Pharmaceuticals, Inc.: R&D Expenditure, 2017-2019
Figure 13.74: Regeneron Pharmaceuticals, Inc.: SWOT Analysis
Figure 13.75: Sanofi SA: Overall Product Portfolio
Figure 13.76: Sanofi SA: Overall Financials, 2017-2019
Figure 13.77: Sanofi SA: Revenue (by Segment), 2017-2019
Figure 13.78: Sanofi SA: Revenue (by Region), 2017-2019
Figure 13.79: Sanofi SA: R&D Expenditure, 2017-2019
Figure 13.80: Sanofi SA: SWOT Analysis
List of Tables
Table 1: Leading Players in Global PD-1/PD-L1 Immunotherapy Market
Table 4.1: Clinical Studies About Pembrolizumab
Table 4.2: Clinical Studies About Nivolumab
Table 4.3: Commercialized PD-1/PD-L1 Products
Table 5.1: Type of Tumors Treated by PD-1/PD-L1 Immunotherapy
Table 6.1: Share of Patents Filed, January 2015-December 2019
Table 7.1: Impact Analysis
Table 7.2: Comparison of R&D Expenditure by Major Pharmaceutical Companies, 2018 and 2019
Table 7.3: Most Common Side Effects to PD-1/PD-L1 Immunotherapy
Table 8.1: Regulatory Scenario Across the World
Table 8.2: Expedited Regulatory Designations Around the World
Table 9.1: Keytruda Indications, Usage, and Dose
Table 9.2: Opdivo Indications, Usage, and Dose
Table 9.3: Libtayo Indications, Usage, and Dose
Table 9.4: Phase 2 - Pipeline PD-1 inhibitors
Table 9.5: Phase 3 - Pipeline PD-1 inhibitors
Table 9.6: Tecentriq Indications, Usage, and Dose
Table 9.7: Imfinzi Indications, Usage, and Dose
Table 9.8: Bavencio Indications, Usage, and Dose
Table 9.9: Phase 2 - Pipeline PD-1 inhibitors
Table 9.10: Phase 3 - Pipeline PD-1 inhibitors
Table 10.1: First Line Treatment Options, If Marker is Present: PD-L1 ?1%
Table 10.2: First Line Treatment for Adenocarcinomas, Large Cell and Unknown Types, if Marker is Absent or Unknown
Table 10.3: Next-in-Line Treatment for Adenocarcinomas, Large Cell and Unknown Types, if Marker is Absent or Unknown
Table 10.4: First Line Treatment for Squamous Cell Carcinoma if Marker is Absent or Unknown
Table 10.5: Next-in-Line Treatment for Squamous Cell Carcinoma if Marker is Absent or Unknown
Table 10.6: PD-1/PD-L1 Inhibitors for the Treatment of HCC
Table 10.7: PD-1/PD-L1 Inhibitors for the Treatment of Esophageal Cancer
Table 10.8: PD-1/PD-L1 Inhibitors for the Treatment of Small Cell Lung Cancer
Table 10.9: PD-1/PD-L1 Inhibitors for the Treatment of Urothelial Carcinoma
Table 13.1: AstraZeneca Plc: Pipeline Product Portfolio
Table 13.2: BeiGene, Ltd.: Pipeline Product Portfolio
Table 13.3: Bristol Myers Squibb Company: Pipeline Product Portfolio
Table 13.4: Eli Lilly & Company: Pipeline Product Portfolio
Table 13.5: F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio
Table 13.6: Innovent Biologics, Inc.: Pipeline Product Portfolio
Table 13.7: Merck & Co., Inc.: Pipeline Product Portfolio
Table 13.8: Merck KGaA: Pipeline Product Portfolio
Table 13.9: Novartis AG: Pipeline Product Portfolio
Table 13.10: Pfizer Plc: Pipeline Product Portfolio
Table 13.11: Regeneron Pharmaceuticals, Inc.: Pipeline Product Portfolio
Table 13.12: Sanofi SA: Pipeline Product Portfolio